Wald.ai | $4,000,000 | (Dec 11, 2024)
Normo.ai | $262,657 | (Dec 11, 2024)
Gentrace | $8,000,000 | (Dec 11, 2024)
Certified by Founder
Lodge
Wugen
start up
United States
- St Louis, Missouri
- 17/03/2022
- Unknown
- $200,000,000
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
- Industry Biotechnology
- Website https://www.wugen.com/
- LinkedIn https://www.linkedin.com/company/wugen/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Mainframe | $5,300,000 | (Dec 11, 2024)
Ask Sage, Inc. | $17,000,000 | (Dec 11, 2024)
MoldCo | $3,000,000 | (Dec 11, 2024)
Qnovia, Inc. | $16,000,000 | (Dec 11, 2024)
Wavegate Corporation | $26,000,000 | (Dec 11, 2024)
Stainless | $25,000,000 | (Dec 11, 2024)
SpotmyEnergy | $11,030,280 | (Dec 11, 2024)
Raptor Maps | $35,000,000 | (Dec 11, 2024)
GovSignals | $5,500,000 | (Dec 10, 2024)